Why Does PDRN Keep Turning Up Everywhere?
There is a shift happening in aesthetic medicine that I find increasingly interesting. Some of the treatments being discussed now aren't primarily about adding volume or changing the shape of the face. The idea is to influence the tissue itself: its hydration, repair, extracellular matrix and perhaps the behaviour of the cells living within it.
PDRN and polynucleotides have become part of that conversation. They are DNA-derived materials with proposed effects on cellular signalling and tissue repair, and they are now being used in aesthetic treatments that promise improvements in skin quality rather than simply filling a defect.
That makes me curious about what is actually happening biologically.
Not what the marketing says.
What the tissue is doing.
So what actually is PDRN?
PDRN stands for polydeoxyribonucleotide. It refers to DNA-derived polymers, commonly produced from purified salmonid DNA, which have been investigated in wound healing, tissue repair and dermatology.
It isn't being injected as intact genetic material. The material can be broken down within the biological environment into smaller nucleotide-related components, which may then participate in cellular signalling and nucleotide metabolism.
One proposed pathway involves adenosine A2A receptor signalling, which has been studied in relation to inflammation, angiogenesis and tissue repair. PDRN has also been investigated for effects on fibroblasts and the extracellular environment surrounding them.
A useful overview is *From Polydeoxyribonucleotides (PDRNs) to Polynucleotides (PNs): Bridging the Gap Between Scientific Definitions, Molecular Insights, and Clinical Applications of Multifunctional Biomolecules*.
The important point is that PDRN isn't interesting simply because it contains DNA. The proposed biological effects depend on what happens to that material once it enters a biological environment.
What happens at the cellular level?
There is some surprisingly old experimental work behind the modern aesthetic interest.
In a 1999 study by Thellung and colleagues, Life Sciences, primary human skin fibroblasts from seven donors were exposed to PDRN. The researchers found an increase in fibroblast proliferation and then investigated the possible mechanism using adenosine receptor agonists and antagonists.
The proliferative response was reduced by an A2 receptor antagonist and reproduced by an A2 agonist. PDRN also produced an increase in intracellular calcium, supporting a role for A2-purinergic signalling.
The preparation used in the study consisted predominantly of DNA polymers, and the authors proposed that some of the biological activity could arise after the material was broken down into smaller nucleotides, nucleosides and bases. They also found that the acute calcium response behaved differently from the proliferative response, which led them to consider whether degradation products might participate in the signalling process.
This is useful mechanistic evidence, but it has clear limits. It was a fibroblast study using a particular PDRN preparation under controlled laboratory conditions. It does not establish that every modern PN or PDRN injectable produces the same response in living human skin.
That distinction is easy to lose once a plausible mechanism becomes part of aesthetic marketing.
PDRN isn't the same thing as PN
The terminology doesn't help.
PDRN and PN are related DNA-derived materials, but they are not necessarily interchangeable. Their molecular size and structure can differ, and those differences may affect their physical behaviour, degradation and interaction with tissue.
A recent review proposes a molecular-weight distinction at 1500 kDa, with PDRN below that threshold and PN at or above it. The authors present this as a way of bringing some consistency to a field in which the terms have often been used rather loosely.
I think it is useful as a proposed framework, but I wouldn't treat the cutoff as though it were a universal biological dividing line. A molecular-weight label tells us something about a material. It doesn't tell us exactly how a particular formulation will behave once it is injected.
So does it actually stimulate collagen?
It may contribute to processes that eventually affect collagen production, but "stimulates collagen" is a much simpler statement than the underlying biology.
Fibroblasts respond to growth factors, inflammatory signals, mechanical cues and changes in the extracellular matrix around them. PDRN has been studied in relation to some of those pathways, but the evidence does not establish one simple mechanism that explains every PDRN and PN product now being used in aesthetics.
The clinical literature is similarly encouraging but uneven.
A systematic review of polynucleotides in aesthetic medicine identified nine studies involving 219 patients. Reported outcomes included improvements in wrinkles, skin texture and elasticity, but the studies differed considerably in treatment areas, protocols, injection techniques and outcome measures. The authors considered the overall evidence to be low or moderate quality.
That doesn't mean the treatments don't work. It means the evidence is not yet consistent enough to support very confident claims about exactly how effective they are, which formulations are best, or which biological mechanism accounts for the clinical changes.
The human evidence is growing, but the gaps are still there
A 2026 narrative review of PDRN in post-procedure recovery, PDRN in Post-procedure Recovery in Aesthetic Medicine brought together clinical and preclinical evidence relating to processes such as re-epithelialisation, erythema and scarring.
The overall picture is encouraging, but the authors also point to the limitations of the current literature, including small samples, variation between formulations and relatively limited long-term follow-up.
That leaves us with a useful middle ground.
There is enough evidence to take PDRN biology seriously. There isn't yet enough evidence to turn every proposed mechanism into a definitive statement about regeneration of ageing human skin.
And I think that distinction is worth preserving.
What I find interesting about PDRN
Perhaps the most interesting part is not whether PDRN deserves to be called a "regenerative" treatment.
It is the possibility that an injectable could influence tissue behaviour through several layers of biology at once. The material enters the tissue, is exposed to the local environment, may be broken down into smaller components, and those components can interact with signalling pathways involved in repair. The fibroblast is then responding within its own extracellular environment rather than in isolation.
That makes PDRN rather different from an ordinary filler whose main purpose is to occupy space.
It also makes it difficult to compare every so-called skin booster on the basis of one shared outcome, such as collagen production. The route to that outcome matters.
Where does that leave us?
PDRN has moved a long way from a relatively specialised regenerative compound into the vocabulary of everyday aesthetics. Along the way, the language has expanded too. We now talk about skin quality, repair, bioremodelling, regeneration and tissue health alongside more familiar ideas such as hydration and collagen.
Some of those claims have a reasonable biological basis. Others are much more difficult to establish from the available human evidence.
That is probably why I prefer following the biology back to the tissue itself.
PDRN doesn't need to be a miracle for it to be interesting. The early cellular work gives us a plausible signalling story; the clinical literature gives us some evidence of benefit; and the gaps between those two things tell us where the research still needs to go.
For me, that is the more useful question: what are we actually trying to change when we inject something into ageing skin?
The answer may turn out to be more complicated than collagen.
C·🌷
Research notes
The PDRN literature spans cellular studies, animal research and a relatively small clinical aesthetic literature. The strongest mechanistic evidence discussed here comes from fibroblast experiments, while the human clinical evidence remains more heterogeneous. PDRN and PN are also not consistently distinguished across the literature, which is why claims about molecular weight and mechanism should be treated cautiously.
References
Thellung et al. (1999), Life Sciences. Polydeoxyribonucleotides enhance the proliferation of human skin fibroblasts: involvement of A2 purinergic receptor subtypes. 64(18):1661-1674. doi:10.1016/S0024-3205(99)00104-6.
Lee et al. (2024), Polynucleotides in Aesthetic Medicine. Polynucleotides in Aesthetic Medicine: A Review of Current Practices and Perceived Effectiveness.
The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review.
Polydeoxyribonucleotide in Post-procedure Recovery in Aesthetic Medicine (2026). A Narrative Review.